{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Lim Sam, Lam Chi-Leung David et al. Impact of chronic obstructive pulmonary', 'disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey.', 'Asia Pacific Family Medicine. 2015; 14:4', 'Singh Richa, Mackay AJ et al. Inflammatory thresholds and the species-specific effects', 'of colonising bacteria in stable chronic obstructive pulmonary disease. Respiratory', 'Research. 2014; 15: 114', 'World Health Organization (WHO). Chronic obstructive pulmonary disease (COPD)', 'Fact Sheet. 2015. Available from: http://www.who.int/mediacentre/factsheets/fs315/en/', 'Accessed: 13 February 2017', 'Appendix A Clinical Laboratories', 'Table 14', \"GSK Biologicals' laboratories\", 'Laboratory', 'Address', 'GSK Biologicals Clinical', 'Biospecimen Reception - B7/44', 'Laboratory Sciences (CLS),', \"Rue de l'Institut, 89 - B-1330 Rixensart - Belgium\", 'Global Vaccine Clinical Laboratory,', 'Rixensart', 'GSK Biologicals Clinical', 'Avenue Fleming, 20 - B-1300 Wavre - Belgium', 'Laboratory Sciences (CLS),', 'Global Vaccine Clinica Laboratory,', 'Wavre-Nord Noir Epine', 'Table 15', 'Outsourced Laboratories', 'Laboratory', 'Address', 'Q Solutions Clinical Trials (US)', '27027 Tourney Road, Suite 2E', 'Valencia, CA 91355', 'USA', 'Q\u00b2 Solutions (Singapore)', 'Tan Tock Seng Hospital', 'Dept of Laboratory Medicine', 'Level 2, Podium Block', 'Tan Tock Seng Hospital', '11 Jalan Tan Tock Seng', 'Singapore 308433', '19-OCT-2018', '101', '75661ebdab2e949f7a1f1bc2071b9dec72acecci']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'GlaxoSmithKline Biologicals', 'Vaccine Value & Health Science (VVHS)', 'Protocol Amendment 2', 'eTrack study number', '201112 (EPI-NTHI-001 BOD APA)', 'and Abbreviated Title', 'Amendment number:', 'Amendment 2', 'Amendment date:', '20 October 2017', 'PPD', 'Co-ordinating author:', 'Scientific Writer', 'Rationale/background for changes:', 'The protocol has been amended to implement the following changes:', 'The study procedure with respect to pre- and post-bronchodilator spirometry', 'during the screening visit has been amended in order to clarify that if a good', 'quality spirometry was not obtained, the test can be repeated (preferably within', '7', \"days of the previous spirometry) as per investigator's medical judgement.\", 'Update of the laboratory section to better clarify that:', '-', 'The PCR on H. influenzae isolate samples allows discrimination of Hi from', 'non-Hi & identification of NTHi. Furthermore, reference to H. haemolyticus', 'has been deleted from the protocol as the PCR that will be performed on', 'bacterial Hi isolates is designed to identify H. influenzae and not', 'H. haemolyticus.', 'The cohorts for analyses have been updated as the PP analysis is not applicable to', 'this specific study design, as all patients will be included in the analysis.', 'Furthermore, according to ICH E9 recommendation a Full Analysis Set (FAS),', 'All Screened set and All Enrolled Set have been added.', 'To correct some typographical errors.', 'Removal of the R and symbols in the document and simplification of the copyright', 'TM', \"statement as per GSK Legal Global Trade Marks (LGTM) department's\", 'recommendation.', 'Amended text has been included in bold italics and deleted text in strikethrough in the', 'following sections:', 'Contributing authors', 'PPD', 'and', 'PPD', 'PPD', 'and', 'PPD', 'PPD', 'and', 'PPD', ',', 'Clinical Safety Representatives', '19-OCT-2018', '102', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']\n\n###\n\n", "completion": "END"}